Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 8,462 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolism Disorder, Glucose Clear all

Conditions: Hypoglycemia
Interventions: Naltrexone High Dose, Naltrexone Low Dose; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Smartphone diabetes management application; Behavioral
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: WW Intervention, Usual Care; Behavioral · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Baton Rouge, Louisiana • Greensboro, North Carolina • Pittsburgh, Pennsylvania

Conditions: Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
Interventions: HiDO-ALZ; Device
Lead sponsor: HiDO Technologies; Industry
Eligibility: 65 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity, Vitamin D Deficiency
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 10 Years to 18 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metabolic Syndrome, Lipotoxicity
Interventions: Valsartan, Hydrochlorothiazide; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Albiglutide, Insulin Glargine and Insulin Lispro; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 814 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 39
States / cities: Searcy, Arkansas • Huntington Beach, California • Long Beach, California + 34 more

Conditions: Type 2 Diabetes, Microvascular Dysfunction
Interventions: Intensive risk factor management; Other
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions: Tirzepatide; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Type 1 Diabetes Mellitus, Exercise Physiology
Interventions: Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring; Behavioral · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 3 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Stanford, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Conditions: Obesity, Dysglycemia
Interventions: Betaine, Placebo; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Gestational
Interventions: Text-message reminder; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Periodontal Disease
Interventions: Investigational Procedure; Procedure
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Iowa City, Iowa • Somerville, Massachusetts • Stony Brook, New York + 1 more

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitoring (CGM), Adaptive dietary intervention (GEM); Device · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Cardiovascular Disease
Interventions: Low support, Medium support, High support, Comparison; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type 1 Diabetes Mellitus
Interventions: Verapamil, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Coronary Artery Disease, Angina, Metabolic Syndrome
Interventions: Ranolazine; Drug
Lead sponsor: Atlanta Heart Specialists, LLC; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Cumming, Georgia • Tucker, Georgia

Conditions: Diabetes
Interventions: Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing; Drug · Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lipodystrophy
Interventions: Metreleptin; Biological
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 14 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes
Interventions: Daily text messages; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Diabetes, Gestational
Interventions: Lifestyle and Risk Assessment class; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diseases, Metabolic, Insulin Sensitivity
Interventions: Intralipid, ClinOleic, Dextrose, Saline (control); Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

Graded Insulin Suppression Test P&F

Acceptability & Impact of a Diabetes Management Smartphone App (mySugr) for Spanish-literate Adults With Type 2 Diabetes

Improving Glycemic Control Using a Virtual Weight Control Program Among Adults With Type 2 Diabetes

Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation

Vitamin D and Vascular Health in Children

Regression of Fatty Heart by Valsartan Therapy

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus

Tirzepatide for Treatment of CCCA

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors

Metabolic Effects of Betaine Supplementation

Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes

Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age

Adaptive Dietary Intervention (ADI) for Asian Americans With Type 2 Diabetes

SPREAD-NET: PRactices Enabling Adapting and Disseminating in the Safety NET

Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes

Ranolazine, Ethnicity and the Metabolic Syndrome

The Effect of Dopamine on Diabetic Retinopathy

Short-term Effects of Leptin in People With Lipodystrophy

Trial to Examine Text-message Based mHealth in Emergency Department Patients With Diabetes

Recent GDM Lifestyle Intervention

Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers